Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers
- PMID: 30462849
- DOI: 10.1111/jgh.14547
Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers
Abstract
Background and aim: Combined hepatocellular-cholangiocarcinoma (CHC) is a primary liver cancer containing both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) elements. Its reported clinicopathological features and prognoses have varied because of its low prevalence. This study aimed to clarify these aspects of CHC.
Methods: We enrolled 28 patients with CHC, 1050 with HCC, and 100 with ICC and compared the clinicopathological characteristics and prognosis of CHC with HCC and ICC. We also analyzed prognostic factors, recurrence patterns, and management in CHC patients.
Results: The incidences of hepatitis B virus and high α-fetoprotein and protein induced by vitamin K absence or antagonists-II levels were significantly higher among CHC compared with ICC patients. Multiple tumors were more frequent in CHC compared with the other groups, while vascular invasion and lymph node metastasis were more frequent in the CHC than the HCC group. The 5-year overall survival and disease-free survival rates for CHC were 25.1% and 22.6%, respectively. Overall survival was significantly lower than for HCC (P < 0.001) but not ICC (P = 0.152), while disease-free survival was significantly lower than for HCC and ICC (P = 0.008 and P = 0.005, respectively). Multivariate analysis identified carcinoembryonic antigen levels and tumor size as independent predictors in patients with CHC.
Conclusions: The clinical features of CHC, including sex, hepatitis B virus infection, α-fetoprotein, and protein induced by vitamin K absence or antagonists-II levels, were similar to HCC, while its prognosis and pathological features, including vascular invasion and lymph node metastasis, were similar to ICC. Carcinoembryonic antigen levels and tumor size were independent prognostic factors in patients with CHC.
Keywords: combined hepatocellular-cholangiocarcinoma; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; prognosis; resection.
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Similar articles
-
Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.Chin J Cancer. 2016 Aug 24;35(1):82. doi: 10.1186/s40880-016-0146-7. Chin J Cancer. 2016. PMID: 27552844 Free PMC article.
-
Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.Am J Surg Pathol. 2016 May;40(5):608-16. doi: 10.1097/PAS.0000000000000579. Am J Surg Pathol. 2016. PMID: 26735856
-
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27. Ann Surg Oncol. 2012. PMID: 22451237
-
Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) originating from hepatic progenitor cell: a case report and review of the literature.World J Surg Oncol. 2016 Aug 17;14(1):218. doi: 10.1186/s12957-016-0974-6. World J Surg Oncol. 2016. PMID: 27535234 Free PMC article. Review.
-
Synchronous double primary hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A case report and review of the literature.Medicine (Baltimore). 2021 Nov 19;100(46):e27349. doi: 10.1097/MD.0000000000027349. Medicine (Baltimore). 2021. PMID: 34797273 Free PMC article. Review.
Cited by
-
Clinical application of thioredoxin reductase as a novel biomarker in liver cancer.Sci Rep. 2021 Mar 16;11(1):6069. doi: 10.1038/s41598-021-85688-3. Sci Rep. 2021. PMID: 33727662 Free PMC article. Clinical Trial.
-
Nodal recurrence mapping and clinical target volumes after resection of intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma.Clin Transl Radiat Oncol. 2024 Feb 18;45:100749. doi: 10.1016/j.ctro.2024.100749. eCollection 2024 Mar. Clin Transl Radiat Oncol. 2024. PMID: 38425471 Free PMC article.
-
Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.Abdom Radiol (NY). 2023 Jun;48(6):2019-2037. doi: 10.1007/s00261-023-03879-0. Epub 2023 Mar 24. Abdom Radiol (NY). 2023. PMID: 36961531 Review.
-
Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma.J Oncol. 2021 Dec 10;2021:3002480. doi: 10.1155/2021/3002480. eCollection 2021. J Oncol. 2021. PMID: 34925507 Free PMC article.
-
Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.Cancer Med. 2022 Jan;11(2):317-331. doi: 10.1002/cam4.4448. Epub 2021 Dec 5. Cancer Med. 2022. PMID: 34866356 Free PMC article.